Invitation - Orexo Capital Markets Day, Stockholm, Sweden, March 17

Uppsala, Sweden - February 19, 2020 - Orexo AB (publ.), today invites investors, analysts and media to attend the company's Capital Markets Day, taking place in Stockholm, Sweden, on

March 17, at Helio GT30, Grev Turegatan 30.

Members of Orexo's management team, including recently appointed EVP Digital Therapeutics, Dennis Urbaniak, will provide an update on the company's strategy, R&D pipeline and business opportunities within digital health. Also speaking will be Dr. Mario Weiss, CEO and Founder of GAIA AG, a global leader in digital therapeutics.
The agenda for the day is displayed below. To register for the event please use the following link

https://financialhearings.com/event/12588/register/live_event  

   Time Topic or activity Presenter
pm CET
  1:00 - Registration and coffee  
1.30
       
Part 1 -
Growth
Strategy
  1:30 - Strategy for short- and Nikolaj Sørensen, CEO
1:50   long-term growth  and President 
  1:50 - Growing the Zubsolv® Robert DeLuca,
2:10 franchise President of
Orexo US Inc.
       
Part 2 -
Pharma R&D
Pipeline
   2:10 - A pipeline with Johannes Doll, EVP
2:30  significant future and
potential  Chief Commercial
Officer
  2:30 - Q&A session  
2:35 
  2:35 - Break  
2:45 
       
Part 3 -
Digital
Therapeutics
(DTx)
  2:45 - DTx - new frontiers in Dennis Urbaniak,
3:10    patient care EVP Digital
Therapeutics
  3:10 - GAIA - a global leader Dr. Mario Weiss, CEO
3:40  in digital therapeutics and founder of GAIA
AG
   3:40 - Q&A session  
3:55
   3:55 - Concluding remarks Nikolaj Sørensen, CEO
4:00 and President
   4:00 Mingle and buffet  

Robert Rönn, VP and Head of R&D, and Mike Sumner, Chief Medical Officer, will attend the
Q&A sessions.

Minor changes can be done in the agenda ahead of the event.

For further information, please contact:

Orexo AB (publ.)  
Lena Wange, IR and Communications Manager  
Tel: +46 (0)18 780 88 00  
Email: ir@orexo.com  

About Orexo

Orexo develops and commercializes improved pharmaceuticals and digital therapeutics, addressing unmet medical needs mainly within the growing space of addiction. Approved products are commercialized by Orexo in the US or worldwide via partners. Orexo's main market is the US for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv®, for the treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 844.8 million and the number of employees was 128. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl,LinkedIn and YouTube.

The information was submitted for publication at 8:00 am CET, on February 19, 2020.